CAMP4 Therapeutics Nasdaq Camp expects data from its Phase 1 2 study of Cmp-002, its experimental treatment for SYNGAP1-related disease, in the first half of 2028, CEO Josh Mandel-Brehm said during a company presentation
Why Is CAMP4 Therapeutics Corporation (CAMP) Stock Up Today?
Updated Nov 17, 2026 7:30 PM ET · Prev Close $3.86
Primary Move Catalyst & Conviction
60% Signal ConvictionOutperforming sector by 6.3%
This stock is significantly outperforming its Pharmaceuticals & Therapeutics sector peers, suggesting a stock-specific catalyst.
Market & Sector Relative Strength
CAMP outperforming the S&P 500 by +5.83%Recent CAMP Catalyst Headlines
Verified WireCAMP4 Therapeutics Nasdaq Camp expects initial data from its SYNGAP1 clinical program in the first half of 2028, as the company prepares to begin dosing patients with a treatment designed to increase expression of a gene
CAMP4 Therapeutics Corporation CAMP delivered earnings and revenue surprises of 15.00 and -5.52 , respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Received authorization in the United Kingdom and European Union to expand global first-in-human Ascend Phase 1 2 clinical trial of Cmp-002 in patients with SYNGAP1-related disorder, adding to clearances in Australia and
1–3 Day Expected Range & Key Level
45% Follow-ThroughWatch for continuation above $4.05
Technical Regime (CAMP)
MIXED MA TREND1-Year Historical Move Analogs
67 EventsSessions in the past year where CAMP moved >3.0% up:
Retail & Crowd Sentiment
NeutralStockTwits messages indicate bullish sentiment towards $CAMP, with traders anticipating a potential price increase to $4.50 by the end of the day and looking forward to the upcoming earnings report. No recent news articles were available for analysis.
About CAMP4 Therapeutics Corporation
Camp4 Therapeutics Corp is a clinical stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervou...
Get Instant CAMP Catalyst Alerts
Receive an email alert when CAMP triggers an unusual volume breakout, options sweep, or rating shift.
Other Liquid Stocks Moving Today
All Today's MoversCAMP Session & Catalyst FAQ
Why is CAMP stock up today?
This stock is significantly outperforming its Pharmaceuticals & Therapeutics sector peers, suggesting a stock-specific catalyst.
Is CAMP stock a buy or sell right now?
Today's session carries a 60% catalyst conviction score on 0.86x relative volume (low participation). Our multi-factor model currently rates CAMP as HOLD. Review full valuation, quality, and timing signals on the CAMP Buy or Sell Decision Brief →
What is CAMP's intrinsic value and expected trading range?
At $4.05, CAMP's modeled 1-to-3 session range is $3.97 – $4.17, with a key inflection level at $4.25 (resistance). Compare current price against multi-year cash flow projections in the CAMP Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
What do RSI and moving averages signal for CAMP?
RSI at 53.3 reflects constructive bullish momentum. CAMP trades at $4.05 relative to its 20-day SMA ($3.82) and 50-day SMA ($3.84), reflecting a mixed moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.